CanSinoBIO’s vaccine is a recombinant viral vector vaccine, a class of vaccines that use a modified version of a different virus to deliver instructions to cells that trigger an immune response.

Convidecia is under clinical development by CanSino Biologics and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

It is hard to overestimate the importance of antibodies in the frameworks of biotechnology and pharmaceutical industries.

A recombinant vaccine is a vaccine produced through recombinant DNA technology. This involves inserting the DNA encoding an antigen (such as a bacterial surface protein) that stimulates an immune ...

Following the success of Humulin, recombinant DNA technology was quickly adopted to replace older methods of producing medical products from human growth hormone to vaccines. Although scientists have ...

These responses are five- to tenfold higher than the T-cell responses induced by the DNA vaccine or recombinant MVA vaccine alone, and produce partial protection manifest as delayed parasitemia ...

In the context of the NIH Guidelines for Research Involving Recombinant DNA Molecules, recombinant DNA molecules are defined as either: molecules that are constructed outside living cells by joining ...